Naldemedine
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide
|
|
| Clinical data | |
| Routes of administration |
Oral |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | 916072-89-4 1345728-04-2 (tosylate) |
| ATC code | None |
| PubChem | CID 135626906 |
| ChemSpider | 28530803 |
| Chemical data | |
| Formula | C32H34N4O6 |
| Molar mass | 570.63556 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist under development by Shionogi for the treatment of opioid-induced adverse effects including constipation, nausea, and vomiting.[1][2][3] Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects.[2] No effects indicative of central opioid withdrawal or impact on the analgesic or mydriatic effects of co-administered opioids have been observed.[1] As of July 2014, naldemedine is in phase III clinical trials in the United States and Japan.
See also[edit]
References[edit]
- ^ a b De Sarro, Giovambattista; Kelly S. Sprawls; Egilius L.H. Spierings; Dustin Tran (2012-03-07). "Drugs in Development for Opioid-Induced Constipation" (PDF). In Catto-Smith G., Anthony. Constipation - Causes, Diagnosis and Treatment. p. 7. doi:10.5772/30377. ISBN 978-953-51-0237-3. Retrieved 12 May 2012.
- ^ a b Shionogi (2009-03-27). "Research and Development at Shionogi (as of March 2009)" (PDF). Retrieved 2012-05-12.
- ^ Nagase H, Fujii H (2011). "Opioids in preclinical and clinical trials". Topics in Current Chemistry. 299: 29–62. doi:10.1007/128_2010_74. PMID 21630515.
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
